Skip to main content
Premium Trial:

Request an Annual Quote

Sanger-Led Project to Study Ethics of Genome Sequencing Studies


The Wellcome Trust Sanger Institute is conducting a study to collect public opinion on how genomic information collected during research studies should be used.

The Genome Ethics project is being led by Anna Middleton, an ethics researcher and genetic counselor, and Mike Parker, a professor of bioethics and director of the Ethox Center at the University of Oxford.

The study includes an online questionnaire that is open to the public and seeks to address questions such as whether to return whole-genome sequencing results to volunteers that participate in research, and, if so, whether some results such as risk variants for diseases for which there is no cure, like Alzheimer's, should be returned.

Results from the study will be used to guide policy decisions.

The Genome Ethics study is part of a larger project at the Sanger Institute, called the Deciphering Developmental Disorders Study, that seeks to find a molecular cause for undiagnosed diseases by sequencing affected children and their families.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.